A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutations

BACKGROUND: The CCR5 antagonist maraviroc (MVC) inhibits human immunodeficiency virus type 1 (HIV-1) entry by altering the CCR5 extracellular loops (ECL), such that the gp120 envelope glycoproteins (Env) no longer recognize CCR5. The mechanisms of HIV-1 resistance to MVC, the only CCR5 antagonist li...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Roche, Michael, Salimi, Hamid, Duncan, Renee, Wilkinson, Brendan L, Chikere, Kelechi, Moore, Miranda S, Webb, Nicholas E, Zappi, Helena, Sterjovski, Jasminka, Flynn, Jacqueline K, Ellett, Anne, Gray, Lachlan R, Lee, Benhur, Jubb, Becky, Westby, Mike, Ramsland, Paul A, Lewin, Sharon R, Payne, Richard J, Churchill, Melissa J, Gorry, Paul R
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3648390/
https://ncbi.nlm.nih.gov/pubmed/23602046
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1742-4690-10-43
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados